# A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children

> **NCT03292588** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 335 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Mepolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03292588
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-07
- **Primary completion:** 2021-04-20
- **Final completion:** 2021-04-20
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2022-07-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292588, "A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03292588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*